Dual blockades of TIM-3 and PD-1 effectively prevent hyper-progression and enhance the efficacy of anti-PD-1 therapy in high-grade serous ovarian cancer. The gene discussed is PDCD1; the disease is ovarian serous adenocarcinoma.